Moderna (MRNA) Surges on AI-Driven Cancer Vaccine Potential - Stockxpo - Grow more with Investors, Traders, Analyst and Research

Moderna (MRNA) Surges on AI-Driven Cancer Vaccine Potential

Moderna (MRNA, Financial) saw a significant stock price increase, closing up 7.27% at $38.50 per share, following Oracle Chairman Larry Ellison’s remarks on the potential of artificial intelligence (AI) in developing mRNA cancer vaccines. Ellison highlighted AI’s role in creating personalized cancer vaccines and early tumor detection. He explained that AI can analyze tests identifying tiny tumor fragments in the blood, leading to the development of personalized cancer vaccines within approximately two days.

Ellison emphasized that once cancer tumors are genetically sequenced, vaccines can be designed for individuals to combat specific cancers. This can be achieved in about 48 hours using AI-driven robots to manufacture mRNA vaccines.

Moderna has collaborated with OpenAI to integrate ChatGPT Enterprise into its operations, aiming to accelerate drug development. Additionally, Moderna is working with Merck (MRK) on the personalized cancer vaccine mRNA-4157, which is in the late stages of development for melanoma patients.

Other AI-focused drug developers also experienced stock gains. AbCellera Biologics (ABCL) rose 15.36%, Absci (ABSI) increased by 25.16%, Schrodinger (SDGR) climbed 14.11%, Ginkgo Bioworks (DNA) gained 11.40%, Tempus AI (TEM) went up 5.90%, and Recursion Pharmaceuticals (RXRX) advanced 8.87%.

Leave a Reply

Your email address will not be published. Required fields are marked *

scroll to top